Pinealon

Pinealon is a synthetic tripeptide, a short chain of just three amino acids (glutamyl-aspartyl-arginine, or EDR), developed within the Russian peptide bioregulator program associated with the St. Petersburg school of V.Kh. Khavinson ². It is studied as a neuroprotective and geroprotective agent: research asks whether it can protect brain cells and slow biological aging ².

Its distinguishing feature is the proposed mechanism. Rather than binding a surface receptor like most drugs, Pinealon enters the cell nucleus, binds DNA and histone proteins, and shifts gene expression. That makes it an epigenetic agent, one that changes how genes are read rather than the genetic code itself ⁴.

Published human studies are small, uncontrolled cohorts in Russian occupational and geriatric medicine. They report improved biological-age markers, psychoemotional stability, and adaptive capacity in elderly patients and professional drivers, often when Pinealon is combined with the related peptide Vezugen ⁹.

What the research examines

• Age-related cognitive decline and biological aging: elderly and worker cohorts showed improved biological-age indicators after short courses ⁹.
• Occupational stress and psychoadaptive disorders: 150 professional drivers improved on psychoemotional indices and borderline-mental-disorder risk ¹⁶.
• Neuroprotection in preclinical models: Alzheimer's and Huntington's models, hypoxia, ischemia, and prenatal stress studies report protective effects ³.
• Cognitive performance in primates: aged monkeys showed improved cognition and partial restoration of neuroimmunoendocrine balance ².

Pinealon is not approved as a drug by the FDA or EMA, and no randomized controlled trial exists for any indication ¹.

Pinealon's defining feature is its proposed mechanism: instead of binding a receptor on the cell surface, the peptide enters the cell and its nucleus and interacts directly with DNA ⁴. Fluorescent-labeling studies place it in the cytoplasm, nucleus, and nucleolus, confirming nuclear uptake in cell assays ¹⁸.

Once inside, it binds DNA sequence-specifically, preferring CNG and CAG motifs, and it can distinguish methylated from unmethylated cytosine, a chemical tag that influences whether genes are active ⁵. It also binds the tail regions of histone proteins (H1, H2B, H3, H4), which package DNA, giving it a second lever on gene accessibility at the chromatin level ²⁴.

Key targets

• DNA: partial insertion into the major groove, contacting guanine; magnesium ions promote binding ⁵.
• Histones: site-specific binding to the tails of core and linker histones ²⁴.
• Gene promoters: docking modeled at the promoter regions of CASP3, APOE, SOD2, PPARA, and PPARG, among others implicated in Alzheimer's disease ³.
• Serotonin pathway: stimulates serotonin synthesis through the tryptophan hydroxylase gene ¹¹.

Downstream, this is reported to tune expression of genes that control programmed cell death (caspase-3, p53), antioxidant defense (SOD2, GPX1), and metabolism-related transcription factors (PPARA, PPARG) ⁴. In cells and animals that translates into preserved dendritic spines, the small protrusions on neurons where synapses form, and reduced oxidative stress ³.

Human cohorts

All published human data are small and uncontrolled, but the direction is consistent. Locomotive crew workers taking 100 mcg orally twice daily for 14 days showed improved biological-age and adaptive-reaction parameters ¹⁷. In 150 professional drivers with psychoadaptive disorders, Pinealon combined with Vezugen improved psychoemotional indices and reduced occupational risk of borderline mental disorders ¹⁶. In a 110-person comparative study, the Pinealon plus Vezugen pairing produced the most pronounced improvements in biological-age indicators among the interventions tested ⁹. In 32 polymorbid patients aged 41 to 83, the combination improved CNS function while slowing biological aging ¹⁰. Memory improvement in elderly patients is also reported in the review literature ⁴.

Preclinical models

In aged monkeys, EDR-class peptides improved cognition and helped restore neuroimmunoendocrine balance ². In Alzheimer's disease models, EDR at 200 ng/ml restored mushroom-shaped dendritic spines by 71% in amyloid-treated hippocampal neurons ⁶ and prevented spine loss in 5xFAD mice ³. Rodent studies report improved water-maze learning in young and old animals ¹³, better survival after carotid artery occlusion ²⁰, and normalization of inflammatory cytokines after hypoxic stress ¹². In Huntington's disease mice, EDR restored spine morphology on striatal neurons ⁷.

Strength of evidence

The literature comes predominantly from one research lineage, the Khavinson laboratory and collaborators, without independent replication. No randomized, placebo-controlled trial exists for any indication ¹. The mechanistic claims of nuclear entry and DNA binding are the best-supported findings, reproduced across multiple methods ⁵.

Published human regimens

The only fully itemized human regimen in the literature is oral: 100 mcg capsule twice daily (200 mcg/day) for 14 days, studied in locomotive crews and associated with improved biological-age and adaptive-reaction parameters ¹⁷. Geriatric and occupational cohorts used course-based Pinealon plus Vezugen combinations without itemized doses ⁹.

Community research protocols

Injectable community protocols center on subcutaneous dosing of 100-500 mcg/day, typically 200 mcg/day, split into morning and early-afternoon doses, for 10-20 day courses. Intranasal protocols use 100-200 mcg total daily in one or two doses. Community practice also describes a higher-dose acute protocol of 2-3 mg subcutaneously or intramuscularly, as a single dose or once daily for three days, placed around hypoxic or concussive stress. Allometric scaling from the 400 mcg/kg/day intraperitoneal mouse dose in the Alzheimer's model ³ gives a human equivalent of roughly 2.3-3.6 mg for a 70 kg subject, which brackets that acute range.

Timing

Morning dosing is the community standard, and the animal data give a rationale: Pinealon corrected diurnal hypothalamic norepinephrine dynamics in hyperhomocysteinemic rats ²⁵ and stimulates serotonin synthesis in cortical cells ¹¹, an activating profile that fits daytime use. Community practice avoids dosing within about six hours of sleep. The interactive timeline above renders a representative subcutaneous community protocol; the documented oral regimen is a single flat dose with no titration.

Pinealon is the tripeptide Glu-Asp-Arg (EDR), a small, water-soluble peptide ⁵. Community reconstitution practice uses bacteriostatic water containing 0.9% benzyl alcohol as the diluent; the powder dissolves readily and is swirled gently, never shaken. No published stability or reconstitution data exist for this specific peptide.

Storage

• Lyophilized powder: -20°C for long-term stability (1-2 years), or 2-8°C for weeks to months if kept dry and protected from light.
• Reconstituted solution: refrigerate at 2-8°C, upright, in a light-blocking container. Do not freeze after reconstitution; flash-freezing risks degradation and precipitation.
• Shelf life: community practice treats a reconstituted vial as usable for 21-30 days under refrigeration, discarding earlier if turbidity, discoloration, or particulates appear.

Because Glu-Asp-Arg contains no cysteine, methionine, or tryptophan residues, oxidation is a negligible degradation pathway in aqueous solution ⁵. The interactive calculator on this page handles the dilution arithmetic for common vial sizes and target doses.

No formal drug-interaction trials exist for Pinealon; the profile below combines mechanistic studies, animal models, and community practice. The reference human regimen is 100 mcg orally twice daily for 14 days ¹⁷.

Drug classes

• Serotonergics (SSRIs, SNRIs, triptans, MAOIs): theoretical additive serotonergic tone, because Pinealon upregulates serotonin synthesis via the tryptophan hydroxylase gene ¹¹. No human signal exists; monitoring for serotonergic symptoms is the community default.
• NMDA-pathway drugs (memantine, ketamine): possible additive neuroprotection or sedation. Pinealon's antihypoxic action partly limits NMDA-mediated excitotoxicity ²², and it altered hippocampal NMDA-receptor subunit gene expression in diabetic rats ²⁷.
• Sedatives and alcohol: theoretical additive sedation. Pinealon increased sleep time and reduced exploratory and motor activity in aged rats before carotid occlusion ²⁰.
• Cytotoxic chemotherapy: theoretical interference with apoptosis-dependent cell kill, given caspase-3 and p53 modulation and delayed ERK1/2 activation ⁴. Community guidance is to avoid during active cytotoxic therapy without oncology input.
• Stimulants and sympathomimetics: unpredictable direction. Pinealon normalizes diurnal hypothalamic norepinephrine dynamics in rodents ²⁵.
• Antidiabetics: theoretical additive glucose benefit through PPARA/PPARG promoter binding ³; hypoglycemia risk is unquantified.

Epigenetic and pathway drugs

Because Pinealon binds DNA and histones directly ¹⁸, theoretical interactions exist with epigenetic drugs such as valproate or HDAC/DNMT inhibitors, with MEK/ERK-pathway drugs, and with PPAR drugs such as fibrates and thiazolidinediones ³. These remain mechanistic only.

Supplements

• Magnesium: supportive. Magnesium ions promote EDR binding to DNA by screening phosphate charge ⁵; 200-400 mg/day is the community default during cycles.
• High-dose antioxidants (vitamin C, NAC, CoQ10): caution. Pinealon is not a direct radical scavenger, and one human cohort showed prooxidant chemiluminescence during treatment ¹⁰. Dietary intake is fine; avoid antioxidant megadosing.
• Melatonin: compatible. Pineal peptides normalized melatonin/cortisol rhythms in aged primates ².
• 5-HTP and L-tryptophan: moderate caution given serotonin upregulation ¹¹.

Peptide-to-peptide pairings are covered in the stacking section.

Pinealon is used in finite courses rather than continuous dosing, consistent with its class as a recovery- and circadian-modulating peptide ¹. The only documented human course lasted 14 days ¹⁷, and the Russian programs used defined short courses throughout ⁹. Community standards run 10-20-day blocks with off periods at least twice the on-period length, repeated two to four times per year.

Why cycling fits the mechanism

Pinealon acts at the chromatin level: it enters the nucleus, binds DNA at CNG/CAG motifs and histone sites, and shifts transcription ¹⁸. Continuous exposure means sustained transcriptional drive with no reset phase, so interspersed off periods let gene-expression state renormalize between courses. The dose-response is also saturating: cell-protection and antioxidant effects plateau at lower concentrations while genomic modulation continues at higher ones ¹⁹, an argument for capped, time-limited courses rather than dose escalation.

When a break is indicated

Community practice points to diminishing cognitive return, new sleep disruption, fatigue, or mood flattening as signals to stop. The decline in circulating CD34+ hematopoietic cells seen in one elderly cohort ¹⁰ supports checking blood counts if courses run long. No tachyphylaxis, withdrawal, or rebound signal appears in the published cohorts ¹⁶, and effects are described as fading gradually over weeks after a course ends.

Pinealon plus Vezugen

The strongest human outcomes in the literature came from a combination. Vezugen (Lys-Glu-Asp) paired with Pinealon produced the most pronounced biological-age improvements in a 110-person comparative study ⁹ and improved psychoemotional adaptation in 150 professional drivers ¹⁶. The same pairing was used in the polymorbid elderly cohort ¹⁰, and the combination is treated as standard in the Russian geriatric literature ¹⁴.

Pinealon plus Cortexin

Both are neuroprotective peptides, but the evidence frames them as complementary rather than additive. In rats, Pinealon improved Morris water-maze learning more than Cortexin in both young and old animals ¹³. Under hypoxia, Pinealon normalized inflammatory cytokines (IL-6, TNF) toward baseline while Cortexin mainly suppressed programmed cell death and left IL-6 elevated ¹². Practitioner consensus favors sequencing them in separate blocks rather than same-day stacking.

Community pairings

• BPC-157 or TB-500: distinct mechanisms with no known conflict; a common neuro-recovery pairing.
• Growth hormone secretagogues (ipamorelin, CJC-1295): combined for recovery plus cognition with no documented conflict.
• Semax: both are clinical neuroprotectives; community practice uses them interchangeably rather than combined.
• Epitalon: shares nuclear DNA-binding targets ¹⁸; community guidance is to cycle them separately to avoid additive epigenetic load.

Stacking more than one additional neuroactive peptide per cycle is uncommon until individual response is characterized.

Pinealon (Glu-Asp-Arg, EDR) has no FDA, EMA, or MHRA approval for any indication, and no controlled clinical trials exist ¹. It is not scheduled under the US Controlled Substances Act, and no FDA or FTC enforcement action naming Pinealon is on record. US distribution runs through research-chemical vendors rather than registered pharmacy channels, and the compound is absent from the FDA 503A bulk-substances list for compounding.

Documented human administration comes from Russian occupational and geriatric programs, where Pinealon is used as a parapharmaceutical cytogen-class bioregulator rather than a registered drug ⁹.

Sport and anti-doping

No WADA scheduling appears in the available evidence base. Pinealon is not on the WADA Monitoring Program, and no WADA, USADA, or UKAD sanction names it. The residual risk for athletes is adulteration: gray-market vials labeled Pinealon may be mislabeled or carry explicitly prohibited peptides.

Reported profile

No serious adverse events are reported in any published human cohort. Exposed populations include polymorbid elderly patients (32 subjects, ages 41-83), 150 occupational drivers, locomotive crews, and 110 subjects in a comparative geroprotective study ⁹. None of these were randomized trials, so the safety picture is observational ¹.

Laboratory signals to watch

• Prooxidant shift: a prooxidant chemiluminescence signal appeared in the elderly cohort ¹⁰. Cell work shows Pinealon can raise resting intracellular reactive oxygen species while reducing stress-induced ROS and necrotic cell death, consistent with priming endogenous antioxidant enzymes rather than direct scavenging ¹⁹.
• Hematopoietic markers: circulating CD34+ stem and progenitor cells declined in the 32-patient cohort, interpreted as inhibited blood-cell production. No clinical cytopenias were reported, and the finding was never followed longitudinally ¹⁰.
• Sedation-type effects: aged rats showed increased sleep time and reduced motor and motivational behavior after carotid occlusion ²⁰. Mild, transient daytime sleepiness appears in some user reports, plausibly via upregulated cortical serotonin ¹¹.

Theoretical cautions

• Epigenetic/genomic activity: nuclear entry and DNA/histone binding ¹⁸ mean long-term transcriptional consequences are uncharacterized, balanced against the human finding that Pinealon did not alter chromatin condensation ¹⁰.
• Anti-apoptotic profile: suppression of caspase-3 and p53 ⁴ and increased proliferation in aging skin-cell cultures ²⁶ are mechanistically permissive for occult malignancy, with no human oncologic signal.
• Serotonergic additivity: potential interaction with SSRIs, SNRIs, and MAOIs via serotonin synthesis upregulation ¹¹.
• Pregnancy and breastfeeding: no human data. Prenatal administration improved offspring outcomes in hyperhomocysteinemic rats ¹⁵, which does not establish human safety.

Community practice treats active malignancy, bone-marrow suppression, concurrent serotonergic medications, and pregnancy as relative cautions.